



VALIDATE 3rd Annual Meeting
















VENUE: The Grand Hall & Winter Gardens at The Drum at Wembley, London
<https://www.thedrumatwembley.com/>



Tuesday 1 October 2019

[0900-1000 Closed Network Management Board Meeting in Boardroom 2]



The Grand Hall & Winter Gardens – All delegates

Start		Meeting
0915		Registration and tea/coffee
1010		Prof Helen McShane VALIDATE Co-Director, University of Oxford, UK Welcome
1020		Samantha Vermaak VALIDATE Network Manager, University of Oxford, UK An update on VALIDATE at the end of our second year
1040		Talks by most recently funded round #3 projects:
1040		Prof Myron Christodoulides University of Southampton, UK Protective efficacy of conserved <i>Leishmania</i> hypothetical proteins against visceral leishmaniasis (P019)

1053		Dr Barbara Kronsteiner-Dobramysl University of Oxford, UK Metabolic reprogramming of skin microenvironment for improved BCG vaccine efficacy (P020)
1106		Dr Sasha Larsen IDRI, USA Development of an RNA based vaccine against Mycobacterium tuberculosis (P021)
1119		Dr Elena Stylianou University of Oxford, UK Developing a mouse model of diabetes to evaluate vaccines for TB and melioidosis (P022)
1132		Dr Julen Tomás Cortázar University College Dublin, Ireland Elucidating the T-cell epitopes and T-cells responses of two B.pseudomallei vaccine antigens (P023)
1145		Emilie Karafillakis LSHTM, UK Monitoring and addressing challenging risks, rumours and reputations across the GCRF Vaccinology Networks
1200		Lunch
1300		Talks by funded round #1 projects (all now finished):
1300		Sally Hayward SGUL/LSHTM, UK Enhancing BCG efficacy: the Social Technology Lab Initiative (P002)
1320		Dr Javier Salguero Bodes PHE, UK The effect of BCG vaccination in immune responses against visceral leishmaniasis in a natural (canine) model of infection (P003)
1340		Asst Prof Steve Smith LSHTM, UK How do functional and metabolic characteristics of trained monocytes affect their anti-bacterial activity? (P004)
1400		Dr Panjaporn Chaichana MORU, Thailand Establishment of a functional assay panel to evaluate the role of antibodies in defence against melioidosis and tuberculosis (P007)
1420		Dr Rajko Reljic SGUL, UK Overcoming innate immune tolerance in the respiratory tract for optimal vaccine design (P009)

1440		Dr Bernardo Villarreal-Ramos APHA, UK Natural variation of the bovine lymph node microenvironment and its possible effect on BCG immunogenicity (P011)
1500		Tea/coffee break
1530		Keynote speech: Affiliate Prof Rhea Coler IDRI, USA “Novel TB and Leprosy Vaccines: From the Lab Bench to Clinical Trials” – Rhea will discuss an industry perspective on vaccine development
1615		Panel discussion and Q&A by our funded pump-priming project members about the VALIDATE pump-priming scheme
1700		End of day
1730		Wembley Stadium private tour VALIDATE has organised a ‘behind the scenes’ tour of the world-class Wembley Stadium for those who are interested. Highlights include the England dressing room, the press conference facilities, the Royal Box and the players’ tunnel. This is at VALIDATE’s costs – sign up on the registration form. Find out more about the stadium and its history in UK sport and entertainment, including hosting the 2012 London Olympics and FA Cup Finals, here .
1900		VALIDATE will organise a ‘No host’ dinner for delegates who would like to participate and network further with other members. This will be at each delegates own cost – please sign up on the registration form so we can book a venue for you.

Wed 2 October 2019 – Annual Meeting Day 2 (morning only)

Start	End	Meeting
0830		Tea/coffee
0900		Talks by funded round #2 projects (which are close to finishing):
0900		Dr Mohamed Osman University of York, UK Identification of Leishmania donovani and Mycobacterium tuberculosis– derived proteins on the surface of infected macrophages that are associated with ADCC induction (P012)
0920		Prof Susanna Dunachie University of Oxford, UK Vaccines to target people with diabetes: characterising the pathways of immune response to M. tuberculosis and B.pseudomallei in people with diabetes compared to non-diabetes (P016)

0940		<i>VALIDATE Fellow talks:</i>
0940		Prof Samantha Sampson on behalf of Dr Jomien Mouton University of Stellenbosch, South Africa Identification of latency associated antigens and biosignatures associated with <i>Mycobacterium tuberculosis</i>
0955		Dr Rachel Tanner University of Oxford, UK Characterising the BCG-induced antibody response to inform the design of improved vaccines against <i>M.tuberculosis</i>, <i>M. leprae</i> and <i>M.bovis</i>
1010		<i>Tea/coffee break</i>
1040		<i>Funder talks – aiming to help you find future funding opportunities!</i>
1040		Prof Helen Fletcher UKRI/LSHTM, UK <i>Global Challenges Research Fund (GCRF) and Newton Fund</i>
1100		Dr Peter Hart Wellcome, UK <i>Wellcome Vaccines Funding</i>
1120		Dr Martin Broadstock Medical Research Council (MRC), UK <i>MRC Funding opportunities</i>
1140		Prof Helen McShane VALIDATE Co-Director, University of Oxford, UK Annual Meeting wrap-up
1200	<i>Ends 1300</i>	<i>Lunch (where you will be joined by Science Conference delegates. The day continues into the open Scientific Conference)</i>

Costs of Attending

VALIDATE covers the following costs for its members:

- Annual Meeting registration, plus lunch and refreshments both days

VALIDATE cannot cover accommodation or travel costs. Please note that booking accommodation is the responsibility of the delegate; you can find accommodation suggestions on our [website](#).

VALIDATE offers some travel scholarships, covering travel, accommodation and subsistence costs, for LMIC VALIDATE members via competitive application to the Network Management Board. To find out more about our travel scholarships visit our [website](#).